Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Robert Ingraham

Neurological Surgery North Little Rock, AR Medical Doctor

NPI 1609856269 CMS profile 1120985

5201 Northshore Dr, Ste 100, North Little Rock, AR 72118

Open in the dashboard

General payments

$1,669

19 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Ingraham of North Little Rock, AR is reported in the CMS Open Payments database as having received $1,669 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $183 7
2023 General $356 4
2022 General $218 4
2021 General $112 3
2020 General $800 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Ingraham
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Robert Ingraham were reported at $183. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Robert Ingraham Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $800 $294 $76–$2,174 $114
2021 $112 $387 $105–$2,432 $132
2022 $218 $542 $139–$2,989 $149
2023 $356 $534 $145–$2,697 $160
2024 $0 $574 $155–$3,046 $164
2025 $183 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. MicroAire Surgical Instruments LLC $800 1 payment
  2. Cerapedics, Inc. $406 4 payments
  3. Medacta USA, Inc. $108 1 payment
  4. HD LifeSciences LLC $89 1 payment
  5. SI-BONE, Inc. $51 2 payments
  6. Pacira Pharmaceuticals Incorporated $48 1 payment
  7. Stryker Corporation $30 1 payment
  8. Harmony Biosciences LLC $23 2 payments
  9. Globus Medical, Inc. $23 1 payment
  10. Boston Scientific Corporation $23 1 payment
  11. Other $68 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $869 18 payments
  2. Honoraria $800 1 payment
Products named General payments · program years 2020–2025
  1. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $406 4 payments
  2. MUST $108 1 payment
  3. Hive Cervical $89 1 payment
  4. Iovera $48 1 payment
  5. Zilretta $48 1 payment
  6. OMNICURVE $30 1 payment
  7. SPINEJACK $30 1 payment
  8. VERTAPLEX $30 1 payment
  9. Wakix $23 2 payments
  10. COALITION AGX $23 1 payment
  11. Other $137 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

525

Median for Neurosurgery: 83

Drug cost

$3,765

Median for Neurosurgery: $872

Branded share of claims

29.3%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 95 $1,482
Tizanidine Hcl Generic 180 $859
Cephalexin Generic 75 $328
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $311
Oxycodone Hcl Generic 52 $263
Gabapentin Generic 25 $176
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 24 $153
Tramadol Hcl Generic 26 $99
Methylprednisolone Generic 13 $93

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$110,040

Of which drugs: $762

Medicare patients

182

Average age 74

Services billed

692

114 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Depression 29%
Diabetes 27%
Chronic kidney disease 21%
Atrial fibrillation 18%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 48 136 $754

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record